장기지속형 항정신병약물의 임상 실제

• 영문명: The Long-Acting Injectable Antipsychotics in Clinical Practice
• 발행기관: 대한신경정신의학회
• 저자명: 이규영(KyuYoung Lee)
• 간행물 정보: 『신경정신의학』제58권 제1호, 29~37쪽, 전체 9쪽
• 주제분류: 의약학 > 정신과학
• 파일형태: PDF
• 발행일자: 2019.02.28

영문 초록

Symptomatic relapse is observed frequently and often associated with social and/or occupational decline that can be difficult to reverse in patients with schizophrenia. Several atypical antipsychotics, including risperidone, olanzapine, paliperidone, and aripiprazole, have become available as long-acting injectable antipsychotics (LAIs), and new evidence has been accumulating. LAIs appear to have a significant role in at least a group of schizophrenia patients. Improving the adherence, continuous availability, managing changes in receptor sensitivity, and lowering the requirement of cumulative doses are some of the major advantages of LAIs. Patients with first episode psychosis, dopamine super-sensitivity syndromes, and comorbid substance abuse might particularly benefit. Delaying the initiation of LAI until the establishment of non-adherence is not recommended. The results of clinical trials comparing LAIs with oral antipsychotics (OAPs) are inconsistent because they are influenced considerably by the study design. On the other hand, several barriers to LAIs use in current practice include clinical lack of knowledge, and negative attitudes about LAIs. This article tries to help clinicians better characterize the role of LAIs in the treatment of schizophrenia.

목차

서 론

비정형 장기지속형 주사형 항정신병 약물들(LAIs)

임상시험을 통한 비정형 LAIs의 효과와 안정성

장기지속형 항정신병약물들의 약리학적 특성

장기지속형 약물의 임상 실제

결 론

키워드

Schizophrenia Long-acting injections Antipsychotics Medication adherence